

Odactra[™] House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) – Expanded indication

- On January 20, 2023, the <u>FDA approved</u> ALK-Abello's <u>Odactra House Dust Mite</u>
 (<u>Dermatophagoides farinae and Dermatophagoides pteronyssinus</u>), as immunotherapy for the
 treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis,
 confirmed by positive in vitro testing for IgE antibodies to <u>Dermatophagoides farinae</u> or
 Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house
 dust mite allergen extracts. Odactra is approved for use in persons 12 through 65 years of
 age.
 - Odactra was previously approved for this indication in adults only.
 - Odactra is not indicated for the immediate relief of allergic symptoms.
- Odactra carries a boxed warning for severe allergic reactions.
- The most common solicited adverse reactions (≥ 10%) in adolescent patients (12 through 17 years of age) treated with Odactra were throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and diarrhea.
- The recommended dose of Odactra for all ages is one tablet sublingually daily.
 - The first dose of Odactra should be administered in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases.
 - If the patient tolerates the first dose, the patient may take subsequent doses at home.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.